
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

Theravance Biopharma, Inc.

(Name of Issuer)

Ordinary Share \$0.00001 Par Value

(Title of Class of Securities)

(CUSIP Number)

**Weiss Asset Management LP
c/o Georgiy Nikitin, 222 Berkeley St., 16th Floor
Boston, MA, 02116
(617) 778-7725**

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/23/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

Name of reporting person

1

Weiss Asset Management LP

2

Check the appropriate box if a member of a Group (See Instructions)

	☐ (a)
	☐ (b)
3	SEC use only
	Source of funds (See Instructions)
4	WC
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	☐
	Citizenship or place of organization
6	DELAWARE
	Sole Voting Power
7	0.00
Number of	Shared Voting Power
Shares	8
Beneficially	0.00
Owned by	Sole Dispositive Power
Each	9
Reporting	0.00
Person	Shared Dispositive Power
With:	10
	0.00
	Aggregate amount beneficially owned by each reporting person
11	0.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	☐
	Percent of class represented by amount in Row (11)
13	0.0 %
	Type of Reporting Person (See Instructions)
14	IA, PN

Comment for Type of Reporting Person: Row 8, 10, 11, and 13: Please See Item 5

SCHEDULE 13D

CUSIP No.

	Name of reporting person
1	BIP GP LLC
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☐ (b)
3	SEC use only
	Source of funds (See Instructions)
4	WC
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	☐
	Citizenship or place of organization
6	DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power
	0.00	
		Shared Voting Power
	8	
	0.00	
		Sole Dispositive Power
	9	
	0.00	
		Shared Dispositive Power
	10	
	0.00	
		Aggregate amount beneficially owned by each reporting person
11	0.00	
		Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12		☐
		Percent of class represented by amount in Row (11)
13	0.0 %	
		Type of Reporting Person (See Instructions)
14		HC, OO

Comment for Type of Reporting Person: Row 8, 10, 11, and 13: Please See Item 5

SCHEDULE 13D

CUSIP No.

1	Name of reporting person
	WAM GP LLC
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☐ (b)
3	SEC use only
	Source of funds (See Instructions)
4	WC
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	☐
	Citizenship or place of organization
6	DELAWARE
	Sole Voting Power
	7
	0.00
Number of Shares Beneficially Owned by Each Reporting Person With:	8
	Shared Voting Power
	0.00
	Sole Dispositive Power
	9
	0.00
	Shared Dispositive Power
	10
	0.00

11	Aggregate amount beneficially owned by each reporting person
	0.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
	☐
13	Percent of class represented by amount in Row (11)
	0.0 %
14	Type of Reporting Person (See Instructions)
	HC, OO

Comment for Type of Reporting Person: Row 8, 10, 11, and 13: Please See Item 5

SCHEDULE 13D

CUSIP No.

1	Name of reporting person
	Andrew M. Weiss
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☐ (b)
3	SEC use only
4	Source of funds (See Instructions)
	WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
	☐
6	Citizenship or place of organization
	UNITED STATES
	Sole Voting Power
7	0.00
Number of	Shared Voting Power
Shares	8
Beneficially	0.00
Owned by	Sole Dispositive Power
Each	9
Reporting	0.00
Person	Shared Dispositive Power
With:	10
	0.00
11	Aggregate amount beneficially owned by each reporting person
	0.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
	☐
13	Percent of class represented by amount in Row (11)
	0.0 %
14	Type of Reporting Person (See Instructions)
	HC, IN

SCHEDULE 13D

Item 1. Security and Issuer

Title of Class of Securities:

- (a) Ordinary Share \$0.00001 Par Value
- Name of Issuer:

- (b) Theravance Biopharma, Inc.
- Address of Issuer's Principal Executive Offices:

- (c) Ugland House, South Church Street, George Town, CAYMAN ISLANDS , KY1-1104.

Item 1 This Amendment No. 4 (this "Amendment") to Schedule 13D amends the Schedule 13D initially filed on April 12, 2023, (as amended prior to the date hereof, the "Prior Schedule 13D" and, as so amended by this Amendment, the "Schedule 13D") with respect to the items set forth below. Capitalized terms used without definition in this Amendment have the meanings assigned to them in the Prior Schedule 13D.

Item 5. Interest in Securities of the Issuer

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: The percentages set forth above have been calculated based on 51,918,754 shares of the Issuer's Shares issued and outstanding as of July 31, 2026, as reported in the Issuer's Form 8-K, filed with the SEC on September 18, 2026. Each of the Reporting Persons disclaims beneficial ownership of all of the Shares, except to the extent of its or his pecuniary interest therein, and the filing of this Schedule 13D/A shall not be deemed an admission of beneficial ownership of any Shares for any purpose. 0 Shares, representing 0.0% of the outstanding shares of the Issuer, are held by BIP. BIP GP LLC is the general partner of BIP. Weiss Asset Management LP is the investment manager of BIP. Dr. Weiss is the managing member of WAM GP LLC and in such capacity has the power to vote and dispose of such Shares. 0 Shares, representing 0.0% of the outstanding shares of the Issuer, are held by BGO. Weiss Asset Management LP is the investment manager of BGO. Dr. Weiss is the managing member of WAM GP LLC and in such capacity has the power to vote and dispose of such Shares. See cover page above for the aggregate number and percentage beneficially owned by each of the Reporting Persons.

- (a) See Item 5 (a).
- (b) The Reporting Persons did not effect any transactions in the Issuer's Shares during the past 60 days. The Issuer's Shares were cancelled on September 23, 2026 in connection with the completion of the merger with Zymeworks Inc.
- (c) Other than the Funds that directly hold the securities of the Issuer, and except as set forth in this Item 5, no other person is known to have the right to receive, or the power to direct the receipt of, dividends from or proceeds from the sale, of the Shares.
- (d) September 23, 2026
- (e)

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Weiss Asset Management LP

Signature: Georgiy Nikitin
Name/Title: GEORGIY NIKITIN, CHIEF COMPLIANCE OFFICER
Date: 09/25/2026

BIP GP LLC

Signature: Georgiy Nikitin
Name/Title: GEORGIY NIKITIN, CHIEF COMPLIANCE OFFICER
Date: 09/25/2026

WAM GP LLC

Signature: Georgiy Nikitin
Name/Title: GEORGIY NIKITIN, CHIEF COMPLIANCE OFFICER

Date: 09/25/2026

Andrew M. Weiss

Signature: Georgiy Nikitin

Name/Title: GEORGIY NIKITIN, ATTORNEY-IN-FACT
FOR ANDREW M. WEISS**

Date: 09/25/2026

**Comments
accompanying
signature:**

** Duly authorized under Power of Attorney incorporated herein by reference to the exhibit to the Form 13G/A filed by Weiss Asset Management LP on January 25, 2017 in respect of its holding in Quinpario Acquisition Corp. 2.